Archives amgen-ventures

by in
Entry Author Date Location
Ra Pharma Gets $58.5M in Crossover Cash to Target Rare Blood Disease 07/23/15 Boston
Ra Pharmaceuticals Receives $58,500,000 Series B Round 07/23/15 Boston
Precision BioSciences Lands $26M for Gene-Editing Technology 05/11/15 Raleigh Durham
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line 09/18/14 Seattle
MiRagen Therapeutics Raises $7M, Extends Deal with France’s Servier 06/26/14 Boulder/Denver
Atara Biotherapeutics Lands $13,500,000 Series B Round 01/10/14 San Diego
Atara Biotherapeutics Receives $38,500,000 Series B Financing 12/18/13 San Diego
Sutro Biopharma Garners $26,000,000 Series D Funding 12/11/13 San Francisco
VLST, After Nine Years and $50M, Sells Assets and Winds Down 08/07/13 Seattle
Atlas Leans on Amgen, Novartis to Build New Startups 05/16/13 Boston
Ra Pharmaceuticals Clinches Merck Deal for Up to $200 Million 04/01/13 Boston
Theraclone Secures $14M to Push Antibody Drug Programs 03/25/13 Seattle
Theraclone Sciences Garners $14,000,000 Series B Financing 03/25/13 Seattle
Theraclone Sciences Receives $14,000,000 Series B Funding Round 03/25/13 Seattle
Sutro Strikes Celgene Deal Worth Up to $500M 12/18/12 San Francisco
Ra Pharma Pours $8.6M Into Discovery Tech and New Rare-Disease Drug 05/23/12 Boston
Ra Pharmaceuticals Receives $8,600,000 Series A Financing Round 05/16/12 Boston
Sutro Biopharma Pulls in $16M for New Antibody Drugs 05/08/12 San Francisco
MiRagen Therapeutics Garners $20,000,000 Series B Funding Round 04/24/12 Boulder/Denver
Allozyne, Poniard Scrap Plan to Merge Amid Investor Apathy 12/22/11 Seattle
Theraclone Snaps Up $10.6M Financing 09/08/11 Seattle
Theraclone Sciences Secures $10,600,000 Series B Round 09/08/11 Seattle
Ardelyx Nabs $30M To Develop Drug for Irritable Bowel Syndrome, and High Blood Pressure 08/31/11 San Francisco
Ardelyx Garners $30,000,000 Series B Funding 08/31/11 San Francisco
Oncofactor Garners $2,100,000 Series A Financing Round 05/25/11 Seattle
Gilead Buys Calistoga Pharma for $375M, Making Move Into Cancer Drugs 02/22/11 Seattle
Theraclone Strikes $632M Deal With Pfizer to Discover Antibodies for Cancer, Infections 01/18/11 Seattle
Allozyne Passes First Clinical Trial, Dreams Big About a Once-Monthly Multiple Sclerosis Drug 01/10/11 Seattle
Accelerator Reaches Out to East Coast to Find Latest Startup, Acylin Therapeutics 12/01/10 Seattle
Sutro Biopharma Grabs $36.5M in Venture Deal to Make “Biobetters” 11/17/10 San Francisco
Page 1 of 3 next page »